RESUMO
Our objectives were to assess the efficacy and toxicity of gemcitabine plus cisplatin as first-line therapy in metastatic breast cancer (MBC). Patients with stage IV MBC and no prior chemotherapy for metastatic disease were treated with gemcitabine 1200 mg/m on days 1 and 8, and cisplatin 75 mg/m on day 1 every 21 days. Up to 6 cycles were given. A total of 46 patients with a median age of 49 years (range 24-77) and Karnofsky performance status of 80 or above were enrolled. In total, 238 cycles were administered. Of the 42 patients evaluable for response, seven (17%) achieved a complete response and 27 (64%) a partial response, for an overall response rate of 81% [95% confidence interval (CI) 69-93%]. Median time to progression was 14.9 months (95% CI 0-30.2 months). Median duration of response was 24.2 months (95% CI 11.2-37.3 months). The median survival was 27.9 months (95% CI 23.1-32.7 months), and the 1- and 2-year survival probabilities were 71.4 and 61.4%, respectively. All patients were evaluable for toxicity, and grade 3/4 WHO toxicities included neutropenia (41.3%), anemia (8.7%), thrombocytopenia (8.7%), alopecia (26.1%) and nausea/vomiting (32.6%). We conclude that gemcitabine plus cisplatin is a highly effective and safe first-line treatment for patients with MBC. The time to progression of 14.9 months compares favorably with other standard treatments (anthracyclines, taxanes). A randomized study is required to further investigate the role of this combination as first-line treatment for MBC.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Neoplasias da Mama/tratamento farmacológico , Adulto , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Neoplasias da Mama/mortalidade , Neoplasias da Mama/patologia , Cisplatino/administração & dosagem , Cisplatino/efeitos adversos , Desoxicitidina/administração & dosagem , Desoxicitidina/efeitos adversos , Desoxicitidina/análogos & derivados , Feminino , Seguimentos , Humanos , Pessoa de Meia-Idade , Metástase Neoplásica , Análise de Sobrevida , GencitabinaRESUMO
En un análisis retrospectivo de 30 pacientes hipertensos oculares controlados por 11,73 años promedio, encontramos que el 81% de éstos normalizó su PIO a lo largo del tiempo y sólo el 3,3% de ellos desarrolló un glaucoma
Assuntos
Adulto , Pessoa de Meia-Idade , Humanos , Masculino , Feminino , Hipertensão Ocular/epidemiologia , Glaucoma/prevenção & controle , Hipertensão Ocular/reabilitaçãoRESUMO
Se estudia clínicamente el resultado visual y las complicaciones intra y postoperatorias de pacientes portadores de diabetes mellitus operados con cirugía extracapsular e implante de lente intraocular. Se evaluaron 60 casos consecutivos entre enero de 1987 y febrero de 1989 con un seguimiento desde 6 meses hasta 30 meses. Se analiza el comportamiento de la retinopatía diabética en aquellos casos que la presentaban clínicamente y su evolución posterior al implante del lente intraocular. Se estudia la causa del deterioro de agudeza visual en relación a factores de riesgo prefotocoagulación y complicaciones posteriores a la cirugía